# Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy

> **NCT05451719** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 116 (estimated)

## Conditions studied

- Colorectal Cancer
- Colorectal Cancer Stage IV

## Interventions

- **DRUG:** Fruquintinib Plus Capecitabine
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT05451719
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07
- **Primary completion:** 2024-07
- **Final completion:** 2025-07
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05451719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05451719, "Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05451719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*